157 related articles for article (PubMed ID: 38684864)
1. CBX3 antagonizes IFNγ/STAT1/PD-L1 axis to modulate colon inflammation and CRC chemosensitivity.
Xiang Y; Mata-Garrido J; Fu Y; Desterke C; Batsché E; Hamaï A; Sedlik C; Sereme Y; Skurnik D; Jalil A; Onifarasoaniaina R; Frapy E; Beche JC; Alao R; Piaggio E; Arbibe L; Chang Y
EMBO Mol Med; 2024 Jun; 16(6):1404-1426. PubMed ID: 38684864
[TBL] [Abstract][Full Text] [Related]
2. IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling.
Padmanabhan S; Gaire B; Zou Y; Uddin MM; Vancurova I
Cell Signal; 2022 Sep; 97():110400. PubMed ID: 35820543
[TBL] [Abstract][Full Text] [Related]
3. Oxymatrine reduces expression of programmed death-ligand 1 by promoting DNA demethylation in colorectal cancer cells.
Hua S; Gu M; Wang Y; Ban D; Ji H
Clin Transl Oncol; 2021 Apr; 23(4):750-756. PubMed ID: 32737836
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression.
Xu P; Xiong W; Lin Y; Fan L; Pan H; Li Y
Cell Death Dis; 2021 Aug; 12(8):779. PubMed ID: 34365463
[TBL] [Abstract][Full Text] [Related]
5. IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma.
Moon JW; Kong SK; Kim BS; Kim HJ; Lim H; Noh K; Kim Y; Choi JW; Lee JH; Kim YS
Sci Rep; 2017 Dec; 7(1):17810. PubMed ID: 29259270
[TBL] [Abstract][Full Text] [Related]
6. Hyperresponsiveness to interferon gamma exposure as a response mechanism to anti-PD-1 therapy in microsatellite instability colorectal cancer.
Yuan W; Deng D; Jiang H; Tu C; Shang X; He H; Niu R; Dong J
Cancer Immunol Immunother; 2019 Feb; 68(2):257-268. PubMed ID: 30406373
[TBL] [Abstract][Full Text] [Related]
7. Butyrate facilitates immune clearance of colorectal cancer cells by suppressing STAT1-mediated PD-L1 expression.
Zhang Y; Tao Y; Gu Y; Ma Q
Clinics (Sao Paulo); 2023; 78():100303. PubMed ID: 37931529
[TBL] [Abstract][Full Text] [Related]
8. A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma.
van Duijn A; Willemsen KJ; van Uden NOP; Hoyng L; Erades S; Koster J; Luiten RM; Bakker WJ
Cancer Immunol Immunother; 2022 Mar; 71(3):529-540. PubMed ID: 34268602
[TBL] [Abstract][Full Text] [Related]
9. Neurons upregulate PD-L1 via IFN/STAT1/IRF1 to alleviate damage by CD8
Wang Y; Shen Y; Liang J; Wang S; Huang Y; Zhu Q; Zhang X; Yu K; Tong G; Yang C; Li Y; Wang J; Zhao Y
J Neuroinflammation; 2024 May; 21(1):119. PubMed ID: 38715061
[TBL] [Abstract][Full Text] [Related]
10. miREIA - an immunoassay method in assessment of microRNA levels in tumor tissue-pilot study. The impact of miR-93-5p, miR-142-5p and IFNγ on PD-L1 level in colorectal cancer.
Dawidowicz M; Kula A; Mielcarska S; Kiczmer P; Gołąbek K; Ostrowska Z; Waniczek D; Świętochowska E
Acta Biochim Pol; 2021 Apr; 68(2):247-254. PubMed ID: 33826281
[TBL] [Abstract][Full Text] [Related]
11. TGFβ Antagonizes IFNγ-Mediated Adaptive Immune Evasion via Activation of the AKT-Smad3-SHP1 Axis in Lung Adenocarcinoma.
Ye F; Cai Z; Wang B; Zeng C; Xi Y; Hu S; Qu R; Yuan Z; Yue J; Tian Y; Wang X; Fu X; Li L
Cancer Res; 2023 Jul; 83(13):2262-2277. PubMed ID: 37145144
[TBL] [Abstract][Full Text] [Related]
12. Cbx3/HP1γ deficiency confers enhanced tumor-killing capacity on CD8
Sun M; Ha N; Pham DH; Frederick M; Sharma B; Naruse C; Asano M; Pipkin ME; George RE; Thai TH
Sci Rep; 2017 Feb; 7():42888. PubMed ID: 28220815
[TBL] [Abstract][Full Text] [Related]
13. MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells.
Stutvoet TS; Kol A; de Vries EG; de Bruyn M; Fehrmann RS; Terwisscha van Scheltinga AG; de Jong S
J Pathol; 2019 Sep; 249(1):52-64. PubMed ID: 30972766
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers.
Cheng CC; Lin HC; Tsai KJ; Chiang YW; Lim KH; Chen CG; Su YW; Peng CL; Ho AS; Huang L; Chang YC; Lin HC; Chang J; Chang YF
Mol Carcinog; 2018 Nov; 57(11):1588-1598. PubMed ID: 30035369
[TBL] [Abstract][Full Text] [Related]
15. Reciprocal inhibition between TP63 and STAT1 regulates anti-tumor immune response through interferon-γ signaling in squamous cancer.
Jiang Y; Zheng Y; Zhang YW; Kong S; Dong J; Wang F; Ziman B; Gery S; Hao JJ; Zhou D; Zhou J; Ho AS; Sinha UK; Chen J; Zhang S; Yin C; Wei DD; Hazawa M; Pan H; Lu Z; Wei WQ; Wang MR; Koeffler HP; Lin DC; Jiang YY
Nat Commun; 2024 Mar; 15(1):2484. PubMed ID: 38509096
[TBL] [Abstract][Full Text] [Related]
16. Targeting
Le PT; Ha N; Tran NK; Newman AG; Esselen KM; Dalrymple JL; Schmelz EM; Bhandoola A; Xue HH; Singh PB; Thai TH
Front Immunol; 2021; 12():738958. PubMed ID: 34721405
[TBL] [Abstract][Full Text] [Related]
17. Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours.
Martin V; Chiriaco C; Modica C; Acquadro A; Cortese M; Galimi F; Perera T; Gammaitoni L; Aglietta M; Comoglio PM; Vigna E; Sangiolo D
Br J Cancer; 2019 Mar; 120(5):527-536. PubMed ID: 30723303
[TBL] [Abstract][Full Text] [Related]
18. Dissection of PD-L1 promoter reveals differential transcriptional regulation of PD-L1 in VHL mutant clear cell renal cell carcinoma.
Kong SK; Kim BS; Lim H; Kim HJ; Kim YS
Lab Invest; 2022 Apr; 102(4):352-362. PubMed ID: 34789838
[TBL] [Abstract][Full Text] [Related]
19. Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus.
Mineo M; Lyons SM; Zdioruk M; von Spreckelsen N; Ferrer-Luna R; Ito H; Alayo QA; Kharel P; Giantini Larsen A; Fan WY; Auduong S; Grauwet K; Passaro C; Khalsa JK; Shah K; Reardon DA; Ligon KL; Beroukhim R; Nakashima H; Ivanov P; Anderson PJ; Lawler SE; Chiocca EA
Mol Cell; 2020 Jun; 78(6):1207-1223.e8. PubMed ID: 32504554
[TBL] [Abstract][Full Text] [Related]
20. JAK-STAT1 Signaling Pathway Is an Early Response to
Li X; Pan K; Vieth M; Gerhard M; Li W; Mejías-Luque R
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456965
[No Abstract] [Full Text] [Related]
[Next] [New Search]